drugset / Trial / NCT01298310

A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)

NCT01298310

Phase 0 Completed 27 enrolled AstraZeneca
RandomizedCrossoverTriple-blindBasic science

Summary

To characterize the phenotype in patients with Morton's neuroma and to explore the effect of local administration of Xylocaine (lidocaine)

Timeline

Start
2011-02
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified 1 mg/ml Other
Comparator Lidocaine Other / unclassified 10 mg/ml Other

Indications